<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635024</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000589032</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0687</secondary_id>
    <secondary_id>06-005792</secondary_id>
    <nct_id>NCT00635024</nct_id>
  </id_info>
  <brief_title>Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma</brief_title>
  <official_title>A Phase II Trial of Thymoglobulin and Melphalan in Patients With Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as anti-thymocyte globulin, may stimulate the immune
      system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such
      as melphalan, work in different ways to stop the growth of cancer cells, either by killing
      the cells or by stopping them from dividing. Anti-thymocyte globulin may also make cancer
      cells more sensitive to melphalan. Giving anti-thymocyte globulin together with melphalan may
      kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving anti-thymocyte globulin together
      with melphalan works in treating patients with relapsed multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

      * To evaluate the hematological response rate of anti-thymocyte globulin given in combination
      with melphalan in patients with relapsed multiple myeloma.

      Secondary

        -  To assess the toxicity and tolerability of this combination in these patients.

        -  To assess time to disease progression in patients treated with these drugs.

        -  To assess survival of patients treated with these drugs. OUTLINE: Patients receive
           anti-thymocyte globulin IV over 6 hours and melphalan IV on day 1. Treatment repeats
           every 28 days for 6 courses. Patients then receive melphalan alone as above for another
           6 courses. Treatment continues in the absence of disease progression or unacceptable
           toxicity.

      After completion of study treatment, patients are followed every 3 months until disease
      progression and then every 6 months for up to 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to competing trials, this study is permanenlty closed to patient acrrual.
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response</measure>
    <time_frame>4 months</time_frame>
    <description>Response that was confirmed on 2 consecutive evaluations during the first 4 months of treatment.
Complete Response(CR): Disappearance of M-protein from serum and urine, normalization of Free Light Chain (FLC) ratio and &lt;5% plasma cells in bone marrow.
Very Good Partial Response(VGPR): &gt;=90% reduction in serum M-component; Urine M-Component &lt;100mg per 24hours.
Partial Response(PR): &gt;=50% reduction in serum M-component and/or Urine M-Component &gt;=90% reduction or &lt;200mg per 24hours; or &gt;=50% decrease in difference between involved and uninvolved FLC levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>OS was defined as the time from registration to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PFS was defined as the time from registration to progression or death due to any cause.
Progression was defined as any one or more of the following:
An increase of 25% from lowest confirmed response in:
Serum M-component (absolute increase &gt;= 0.5g/dl)
Urine M-component (absolute increase &gt;= 200mg/24hour
Difference between involved and uninvolved Free Light Chain levels (absolute increase &gt;= 10mg/dl)
Bone marrow plasma cell percentage (absolute increase of &gt;=10%)
Definite development of new bone lesion or soft tissue plasmacytomas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>DOR was calculated from the documentation of response (CR, VGPR or PR) until the date of progression in the subset of patients who responded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Non-hematological Adverse Events</measure>
    <time_frame>every month during treatment, up to 12 months</time_frame>
    <description>Severe non-hematologic adverse events were defined as adverse events grade 3 or higher, regardless of attribution to study drug. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Anti-thymocyte Globulin/Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>2.5 mg/kg</description>
    <arm_group_label>Anti-thymocyte Globulin/Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>16 mg/m^2</description>
    <arm_group_label>Anti-thymocyte Globulin/Melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of multiple myeloma

             - Relapsed disease

          -  Must not be a candidate for stem cell transplantation, has refused transplantation, or
             has had stem cells collected previously

          -  Measurable disease, defined by ≥ 1 of the following:

               -  Serum monoclonal protein ≥ 1.0 g by protein electrophoresis

               -  More than 200 mg of monoclonal protein in the urine on 24 hour electrophoresis

               -  Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum
                  immunoglobulin kappa to lambda free light chain ratio

               -  Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-3

          -  Absolute neutrophil count ≥ 1,000/μL

          -  Platelet count ≥ 75,000/μL

          -  Hemoglobin ≥ 8.0 g/dL

          -  CD4 &gt; 100/μL

          -  Creatinine ≤ 3 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active malignancy with the exception of nonmelanoma skin cancer or in situ cervical
             or breast cancer

          -  No uncontrolled infection

          -  No other co-morbidity that would interfere with patient's ability to participate in
             trial

        PRIOR CONCURRENT THERAPY:

          -  No limit to prior therapy

          -  At least 4 weeks since prior melphalan or other myelosuppressive agents

          -  At least 2 weeks since prior non-myelosuppressive agents (e.g., thalidomide or
             high-dose corticosteroids)

          -  No concurrent high-dose corticosteroids

               -  Concurrent chronic steroids (maximum dose 20 mg/day prednisone equivalent)
                  allowed if they are being given for disorders other than amyloid (e.g., adrenal
                  insufficiency or rheumatoid arthritis)

               -  Concurrent continuation of low level/stable steroid doses for replacement or
                  inhalation therapy allowed

          -  Concurrent bisphosphonates allowed

          -  No concurrent immunosuppressive medications such as cyclosporine

          -  No other concurrent investigational treatment

          -  No concurrent cytotoxic chemotherapy or external-beam radiotherapy&gt;

          -  No other concurrent systemic anti-neoplastic therapy including, but not limited to,
             immunotherapy, hormonal therapy, or monoclonal antibody therapy

          -  No concurrent prophylactic hematopoietic growth factors (unless for treatment of an
             established cytopenia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaji K. Kumar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <results_first_submitted>August 27, 2010</results_first_submitted>
  <results_first_submitted_qc>October 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 18, 2010</results_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One (1) patient was recruited from May 2008 to September 2008 at Mayo Clinic. This trial was permanently closed in March 2009 due to competing trials.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Anti-thymocyte Globulin/Melphalan</title>
          <description>Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anti-thymocyte Globulin/Melphalan</title>
          <description>Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Stem Cell Transplant</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parameters of Hematologic Response</title>
          <description>Serum M-Spike &gt;=1 g/dL</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parameters of Hematologic Response</title>
          <description>Serum immunoglobulin free light chain &gt;= 10 mg/dL</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parameters of Hematologic Response</title>
          <description>Urine M-Spike &gt;= 200 mg/24 hours</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parameters of Hematologic Response</title>
          <description>Bone marrow plasma cells &gt; 30%</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response</title>
        <description>Response that was confirmed on 2 consecutive evaluations during the first 4 months of treatment.
Complete Response(CR): Disappearance of M-protein from serum and urine, normalization of Free Light Chain (FLC) ratio and &lt;5% plasma cells in bone marrow.
Very Good Partial Response(VGPR): &gt;=90% reduction in serum M-component; Urine M-Component &lt;100mg per 24hours.
Partial Response(PR): &gt;=50% reduction in serum M-component and/or Urine M-Component &gt;=90% reduction or &lt;200mg per 24hours; or &gt;=50% decrease in difference between involved and uninvolved FLC levels.</description>
        <time_frame>4 months</time_frame>
        <population>One participant was evaluable for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-thymocyte Globulin/Melphalan</title>
            <description>Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)</description>
          </group>
        </group_list>
        <measure>
          <title>Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response</title>
          <description>Response that was confirmed on 2 consecutive evaluations during the first 4 months of treatment.
Complete Response(CR): Disappearance of M-protein from serum and urine, normalization of Free Light Chain (FLC) ratio and &lt;5% plasma cells in bone marrow.
Very Good Partial Response(VGPR): &gt;=90% reduction in serum M-component; Urine M-Component &lt;100mg per 24hours.
Partial Response(PR): &gt;=50% reduction in serum M-component and/or Urine M-Component &gt;=90% reduction or &lt;200mg per 24hours; or &gt;=50% decrease in difference between involved and uninvolved FLC levels.</description>
          <population>One participant was evaluable for the primary endpoint.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from registration to death of any cause.</description>
        <time_frame>up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thymocyte Globulin/Melphalan</title>
            <description>Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from registration to death of any cause.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS was defined as the time from registration to progression or death due to any cause.
Progression was defined as any one or more of the following:
An increase of 25% from lowest confirmed response in:
Serum M-component (absolute increase &gt;= 0.5g/dl)
Urine M-component (absolute increase &gt;= 200mg/24hour
Difference between involved and uninvolved Free Light Chain levels (absolute increase &gt;= 10mg/dl)
Bone marrow plasma cell percentage (absolute increase of &gt;=10%)
Definite development of new bone lesion or soft tissue plasmacytomas</description>
        <time_frame>up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thymocyte Globulin/Melphalan</title>
            <description>Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS was defined as the time from registration to progression or death due to any cause.
Progression was defined as any one or more of the following:
An increase of 25% from lowest confirmed response in:
Serum M-component (absolute increase &gt;= 0.5g/dl)
Urine M-component (absolute increase &gt;= 200mg/24hour
Difference between involved and uninvolved Free Light Chain levels (absolute increase &gt;= 10mg/dl)
Bone marrow plasma cell percentage (absolute increase of &gt;=10%)
Definite development of new bone lesion or soft tissue plasmacytomas</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>DOR was calculated from the documentation of response (CR, VGPR or PR) until the date of progression in the subset of patients who responded.</description>
        <time_frame>up to 2 years</time_frame>
        <population>All patients are non-evaluable - no patients responded to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-thymocyte Globulin/Melphalan</title>
            <description>Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>DOR was calculated from the documentation of response (CR, VGPR or PR) until the date of progression in the subset of patients who responded.</description>
          <population>All patients are non-evaluable - no patients responded to treatment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Non-hematological Adverse Events</title>
        <description>Severe non-hematologic adverse events were defined as adverse events grade 3 or higher, regardless of attribution to study drug. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0)</description>
        <time_frame>every month during treatment, up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thymocyte Globulin/Melphalan</title>
            <description>Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Non-hematological Adverse Events</title>
          <description>Severe non-hematologic adverse events were defined as adverse events grade 3 or higher, regardless of attribution to study drug. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Anti-thymocyte Globulin/Melphalan</title>
          <description>Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Opportunistic Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>After 1 patient was recruited, this trial temporarily closed to allow the first dose of Anti-thymocyte Globulin to be split over two days. Before the modification was written, it was decided to permanently close this study due to competing trials.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Shaji Kumar</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>kumar.shaji@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

